-
I-Mab NasdaqGM:IMAB I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.
Location: 2440 Research Boulevard, Rockville, MD, 20850, United States | Website: https://www.i-mabbiopharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
71.71M
Cash
168.6M
Avg Qtr Burn
N/A
Short % of Float
0.29%
Insider Ownership
11.18%
Institutional Own.
29.54%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Eftansomatropin alfa (TJ101) Details Pediatric growth hormone deficiency | BLA Submission | |
Felzartamab (TJ202) Details Multiple myeloma | Phase 3 Update | |
Lemzoparlimab combo w/ azacitidine Details High risk myelodysplastic syndromes | Phase 3 Update | |
Uliledlimab (TJD5) (TJ004309) +/- toripalimab & +/- pembrolizumab Details Cancer, Non-small cell lung carcinoma | Phase 2 Data readout | |
Uliledlimab (TJD5) (TJ004309) (anti-CD73)+ toripalimab Details Cancer, Non-small cell lung carcinoma | Phase 2 Update | |
Uliledlimab (TJD5) (TJ004309) + toripalimab Details Cancer, Ovarian cancer | Phase 2 Update | |
Efineptakin alfa (TJ107) Details Lymphopenia, Solid tumor/s, Cancer, Triple-negative breast cancer , Head and neck squamous cell carcinoma, Glioblastoma | Phase 2 Update | |
Uliledlimab + pembrolizumab Details Cancer, Non-small cell lung carcinoma | Phase 2 Initiation | |
Felzartamab Details Primary Membranous Nephropathy | Phase 1/2 Update | |
Phase 1b Data readout | ||
MOR210 (TJ210) Details Solid tumor/s, Cancer | Phase 1 Update | |
Ragistomig (TJ-L14B/ABL503) Details Solid tumor/s, Cancer | Phase 1 Update | |
Olamkicept (TJ301) Details Ulcerative colitis, Autoimmune disease | Failed Discontinued | |
Enoblituzumab (TJ271) + Pembrolizumab Details Head and neck cancer, Cancer, Prostate cancer, Solid tumor/s | Failed Discontinued | |
Felzartamab (MOR202) Details IgA nephropathy | Failed Discontinued |